Literature DB >> 18676519

Long-term outcome of the ketogenic diet for intractable childhood epilepsy with focal malformation of cortical development.

Da Eun Jung1, Hoon Chul Kang, Heung Dong Kim.   

Abstract

OBJECTIVE: We evaluated the efficacy and long-term outcome of the ketogenic diet in patients with intractable childhood epilepsy as a result of focal malformation of cortical development.
METHODS: A retrospective analysis evaluated seizure outcomes of 47 patients who had intractable epilepsy from (and) surgically remediable focal malformation of cortical development and were first treated with the classic ketogenic diet, involving the 4:1 lipid/nonlipid ratio. The long-term prognosis of 21 patients, who became seizure-free 3 months after the ketogenic diet, was followed up with that of 22 patients who eventually underwent epilepsy surgery.
RESULTS: Three months after diet initiation, 29 (61.7%) patients showed a reduction in seizure frequency of >50%, including 21 (44.7%) who became seizure-free. Of the 21 patients with complete seizure control at 3 months, 16 (76.2%) successfully completed the diet for 2 years without relapse, and 10 (47.6%) have remained seizure-free after cessation of the diet (mean follow-up for 3 years and 10 months), including 1 patient who remained seizure-free with additional medication after a relapse. Of the 22 patients who underwent epilepsy surgery, a seizure-free outcome was obtained for 13 (59.1%).
CONCLUSIONS: The ketogenic diet should be considered to be an additional option even in patients with focal malformation of cortical development, and long-term seizure-free outcome can be expected for patients who become seizure-free 3 months after the diet.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676519     DOI: 10.1542/peds.2008-0012

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  The changing face of dietary therapy for epilepsy.

Authors:  Ludovica Pasca; Valentina De Giorgis; Joyce Ann Macasaet; Claudia Trentani; Anna Tagliabue; Pierangelo Veggiotti
Journal:  Eur J Pediatr       Date:  2016-09-01       Impact factor: 3.183

2.  The relation of etiology based on the 2017 ILAE classification to the effectiveness of the ketogenic diet in drug-resistant epilepsy in childhood.

Authors:  Markus Breu; Chiara Häfele; Petra Trimmel-Schwahofer; Wolfgang M Schmidt; Franco Laconne; Julia Vodopiutz; Christoph Male; Anastasia Dressler
Journal:  Epilepsia       Date:  2021-08-28       Impact factor: 6.740

3.  Methyl ethyl ketone blocks status epilepticus induced by lithium-pilocarpine in rats.

Authors:  Osamu Inoue; Eriko Sugiyama; Nobuyoshi Hasebe; Noriko Tsuchiya; Rie Hosoi; Masatoshi Yamaguchi; Kohji Abe; Antony Gee
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

4.  An update on the ketogenic diet, 2012.

Authors:  Ayelet Halevy; Lilach Peleg-Weiss; Roni Cohen; Avinoam Shuper
Journal:  Rambam Maimonides Med J       Date:  2012-01-31

Review 5.  Targeted Treatment in Childhood Epilepsy Syndromes.

Authors:  Katharina Vezyroglou; J Helen Cross
Journal:  Curr Treat Options Neurol       Date:  2016-06       Impact factor: 3.598

6.  Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group.

Authors:  Eric H Kossoff; Beth A Zupec-Kania; Stéphane Auvin; Karen R Ballaban-Gil; A G Christina Bergqvist; Robyn Blackford; Jeffrey R Buchhalter; Roberto H Caraballo; J Helen Cross; Maria G Dahlin; Elizabeth J Donner; Orkide Guzel; Rana S Jehle; Joerg Klepper; Hoon-Chul Kang; Danielle A Lambrechts; Y M Christiana Liu; Janak K Nathan; Douglas R Nordli; Heidi H Pfeifer; Jong M Rho; Ingrid E Scheffer; Suvasini Sharma; Carl E Stafstrom; Elizabeth A Thiele; Zahava Turner; Maria M Vaccarezza; Elles J T M van der Louw; Pierangelo Veggiotti; James W Wheless; Elaine C Wirrell
Journal:  Epilepsia Open       Date:  2018-05-21

7.  Treatment strategies for Lennox-Gastaut syndrome: outcomes of multimodal treatment approaches.

Authors:  Ji-Hoon Na; Da Eun Jung; Hee Jung Kang; Hoon-Chul Kang; Heung Dong Kim
Journal:  Ther Adv Neurol Disord       Date:  2022-08-03       Impact factor: 6.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.